ERIS Lifesciences Reports Mixed Q3 Results Amid Rising Sales and Declining Profitability

Feb 04 2025 02:19 PM IST
share
Share Via
ERIS Lifesciences has reported its financial results for the quarter ending December 2024, showcasing a significant year-on-year growth in net sales of 49.59%, totaling Rs 727.45 crore. However, the company experienced an 18.6% decline in Profit After Tax, alongside a 24.88% increase in interest expenses for the half-year period.
ERIS Lifesciences, a midcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results indicate a mixed performance, with net sales showing a notable year-on-year growth of 49.59%, reaching Rs 727.45 crore. This positive sales trend suggests a robust demand for the company's products in the near term.

However, the company's Profit After Tax (PAT) has faced challenges, declining by 18.6% year-on-year to Rs 83.63 crore. This downturn in profitability highlights potential issues that may need addressing. Additionally, interest expenses for the half-year period have increased, growing by 24.88% compared to the previous half-year. This rise in interest costs may reflect higher borrowings, which could impact the company's financial stability moving forward.

In light of these developments, ERIS Lifesciences has experienced an adjustment in its evaluation, with its score reflecting these recent changes.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News